OGEN (Oragenics) Short-Term Debt : $0.33 Mil (As of Dec. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Oragenics Short-Term Debt?

Oragenics's Short-Term Debt for the quarter that ended in Dec. 2024 was $0.33 Mil.

Oragenics's quarterly Short-Term Debt increased from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.52 Mil) but then declined from Sep. 2024 ($0.52 Mil) to Dec. 2024 ($0.33 Mil).

Oragenics's annual Short-Term Debt increased from Dec. 2022 ($0.27 Mil) to Dec. 2023 ($0.31 Mil) and increased from Dec. 2023 ($0.31 Mil) to Dec. 2024 ($0.33 Mil).

Oragenics Short-Term Debt Historical Data

The historical data trend for Oragenics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oragenics Short-Term Debt Chart

Oragenics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

Get a 7-Day Free Trial

0.23

0.30

0.27

0.31

0.33

Oragenics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Short-Term Debt	Get a 7-Day Free Trial															0.31	0.13	-	0.52	0.33

Oragenics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Oragenics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Oragenics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Oragenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (AMEX:OGEN) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

0A64:UK

Address

1990 Main Street, Suite 750, Tampa, FL, USA, 34236

Website

https://www.oragenics.com

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.

Executives

Alan W Dunton	director	VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Fred Telling	director	501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119
John P Gandolfo	director	62 TERRACE ROAD, WAYNE NJ 07470
Cassidy Bruce A. Sr.	director	C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203
Janet Huffman	officer: CFO, Secretary and Treasurer	5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Robert C Koski	director, 10 percent owner	1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Michael O'keefe Sullivan	officer: CFO, Secretary and Treasurer	3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607
Joseph Hernandez	10 percent owner	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Koski Family Lp	10 percent owner	1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Alan Joslyn	director, officer: CEO and President	39 OLD RIDGEBURY ROAD, DANBURY CT 06810
Charles L Pope	director	4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Christine L Koski	director, 10 percent owner	1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243
Thomas L Koski	10 percent owner